What is HC Wainwright’s Forecast for SPRB Q1 Earnings?

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Analysts at HC Wainwright issued their Q1 2027 earnings estimates for Spruce Biosciences in a research report issued to clients and investors on Monday, June 1st. HC Wainwright analyst R. Selvaraju expects that the company will earn ($3.92) per share for the quarter. HC Wainwright has a “Buy” rating and a $150.00 price objective on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($27.49) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q2 2027 earnings at ($3.58) EPS, Q3 2027 earnings at ($2.26) EPS and Q4 2027 earnings at $0.61 EPS.

Spruce Biosciences (NASDAQ:SPRB) last posted its earnings results on Wednesday, May 13th. The company reported ($8.94) EPS for the quarter, missing the consensus estimate of ($7.93) by ($1.01).

Other equities analysts also recently issued reports about the stock. Citizens Jmp lowered their target price on shares of Spruce Biosciences from $170.00 to $150.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Oppenheimer reaffirmed an “outperform” rating on shares of Spruce Biosciences in a research report on Wednesday, May 27th. Finally, Craig Hallum started coverage on Spruce Biosciences in a research report on Monday, April 27th. They issued a “buy” rating and a $140.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $176.60.

Spruce Biosciences Trading Down 1.1%

Spruce Biosciences stock opened at $50.70 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.67 and a quick ratio of 4.67. The company has a market capitalization of $139.53 million, a price-to-earnings ratio of -1.39 and a beta of 3.26. Spruce Biosciences has a one year low of $4.35 and a one year high of $240.00. The company’s fifty day moving average price is $59.11 and its two-hundred day moving average price is $71.89.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stempoint Capital LP bought a new position in Spruce Biosciences during the first quarter worth about $416,000. ADAR1 Capital Management LLC lifted its stake in Spruce Biosciences by 1.0% during the first quarter. ADAR1 Capital Management LLC now owns 58,600 shares of the company’s stock worth $3,830,000 after purchasing an additional 600 shares during the period. SkyView Investment Advisors LLC bought a new position in Spruce Biosciences during the fourth quarter worth about $261,000. Ikarian Capital LLC lifted its stake in Spruce Biosciences by 810.3% during the fourth quarter. Ikarian Capital LLC now owns 121,356 shares of the company’s stock worth $10,571,000 after purchasing an additional 108,024 shares during the period. Finally, Wellington Management Group LLP bought a new position in Spruce Biosciences during the fourth quarter worth about $5,135,000. Institutional investors own 91.71% of the company’s stock.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.